Antibody-drug conjugates: Intellectual property considerations. - Wikidata - awgldk - TriplyDB

Antibody-drug conjugates: Intellectual property considerations.

Antibody-drug conjugates: Intellectual property considerations.

http://www.wikidata.org/entity/Q37138213

about

Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.Patent trend and competitive analysis of cancer immunotherapy in the United States.Marine drugs for cancer: surfacing biotechnological innovations from the oceans

P2860

Q38738155-C09DCE77-B18D-4267-A4C4-335C9B65A8F4 Q46310803-991302ED-3FAD-45ED-8BCE-D7DD9A2A44F0 Q58801183-AD1F3F7D-F894-4237-BA0A-25A783C5497E

P2860

Antibody-drug conjugates: Intellectual property considerations.

http://www.wikidata.org/entity/Q37138213

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 August 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antibody-drug conjugates: Intellectual property considerations.

@en

Antibody-drug conjugates: Intellectual property considerations.

@nl

type

label

Antibody-drug conjugates: Intellectual property considerations.

@en

Antibody-drug conjugates: Intellectual property considerations.

@nl

prefLabel

Antibody-drug conjugates: Intellectual property considerations.

@en

Antibody-drug conjugates: Intellectual property considerations.

@nl

P1433

Q37138213-2FF84588-D19A-4CDF-BEE6-F381F56662D0

P1476

Q37138213-A1374E52-54C7-4F7C-8ACC-48B9C52C13A4

P2093

Q37138213-182FA2F4-4C44-45EE-ACFB-C8478D4CE103

P2860

Q37138213-29771137-FC30-464A-B0AD-3A1C5CFDB614

Q37138213-2D6B9E7F-64C6-4D28-B6C3-8C1529FD5B34

Q37138213-5308FEBC-7F92-4A58-9620-37A0ED38FA81

Q37138213-6349D862-B8F6-4106-BE25-12E99B426B77

Q37138213-90D898E1-B869-490C-8F3E-80F0257A6D85

Q37138213-B6827E8F-0906-4008-82DE-AF05FB037B7B

Q37138213-C3A1B586-ED3B-4849-BCC0-9E4FBFD369FD

Q37138213-D36D437B-4B02-495A-ADCC-5CAD19FE0203

Q37138213-DF83029F-3B28-4AE4-9C54-9433248179E2

Q37138213-E81BEB29-B40E-46B7-84B0-6F655BC10B4E

P304

Q37138213-C49E9A70-E9B1-4169-B166-4A3F68479DA3

P31

Q37138213-6BCAE1CA-9BEC-4414-8B21-C4C841104712

P356

Q37138213-EE9486A2-FE6B-4EA1-9A30-586CCB8DA72C

P433

Q37138213-8FAD7855-4F8C-42A7-9AEA-6469F8E71448

P478

Q37138213-68857EB8-B17A-4E81-B4CE-13009C8AEA75

P577

Q37138213-DB620408-8742-4ABA-A3C8-BA7887766CCC

P698

Q37138213-A27D4782-CD9D-45D4-A3E5-BF7597D949D0

P932

Q37138213-50B1093E-59EA-4A3E-8568-10CE1B9E8F0E

P356

19420862.2015.1082019

P1433

Monoclonal Antibodies

P1476

Antibody-drug conjugates: Intellectual property considerations.

@en

P2093

Ulrich Storz

http://www.w3.org/2001/XMLSchema#string

P2860

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

Rituximab: how approval history is reflected by a corresponding patent filing strategy

Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis.

Antibody conjugate therapeutics: challenges and potential.

Immunoconjugates containing novel maytansinoids: promising anticancer drugs.

Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site

Antibody-drug conjugate target selection: critical factors.

The market for follow-on biologics: how will it evolve?

Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling.

Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases.

P304

989-1009

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/19420862.2015.1082019

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26292154

http://www.w3.org/2001/XMLSchema#string

P932

4966491

http://www.w3.org/2001/XMLSchema#string